Patents by Inventor Hermannus Steen

Hermannus Steen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240174755
    Abstract: The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR ?), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR ? with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR ?. Also provided are PDGFR ? antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 30, 2024
    Applicant: BIORION TECHNOLOGIES B.V.
    Inventors: Hermannus STEEN, Gustaaf Johan Marie VAN SCHARRENBURG
  • Patent number: 9688651
    Abstract: The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X1, X2, X3, X4, X5 and X6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: June 27, 2017
    Assignees: Nyken Holding B.V., Rijksuniversiteit Groningen, Academisch Ziekenhuis Groningen
    Inventors: Bianca Johanna Josephina Maria Brundel, Hermannus Steen, André Heeres, Johannes Paulus Gerardus Seerden
  • Publication number: 20150152076
    Abstract: The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X1, X2, X3, X4, X5 and X6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease.
    Type: Application
    Filed: April 19, 2013
    Publication date: June 4, 2015
    Applicants: NYKEN HOLDING B.V., ACADEMISCH ZIEKENHUIS GRONINGEN, RIJKSUNIVERSITEIT GRONINGEN
    Inventors: Bianca Johanna Josephina Maria Brundel, Hermannus Steen, André Heeres, Johannes Paulus Gerardus Seerden